- IXICO has signed an extension and expansion to its largest existing contract, which was awarded in August 2015, for a phase II/III clinical trial contract in Alzheimer's Disease.

It said the total contract value had increased from US$6.8m to US$7.7m, of which US$1.0m had been recognised to date.

The contract term has been extended by eight months to May 2024.

In this study IXICO utilises its expertise and proprietary technology platform to collect, measure and monitor changes in disease pathology of participants in the trial.

The expansion reflects the addition of additional image data standardisation and collection services, which will be provided over the duration of the study.

Story provided by